DVDmitry L. Vinogradov

Dmitry L. Vinogradov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry L. Vinogradov has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

    by Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova

    Over the last decades, significant progress has been made in studying agonistic and antagonistic hematopoietic peptides. The main disadvantage of this class of peptides is their low stability with noninvasive administration methods, which limits the widespread use of hematopoiesis-regulated peptide drugs in medical practice. The aim of this work is to study novel peptidomimetics with hematopoietic activity sustained in invasive and oral administration. The activity of the leading compound cyclopeptide Cyclo—[Glu(Ile)-Glu(Trp)] (CP-88) was compared to that of the pharmaceutical preparation Stemokin in stimulating the population of committed colony-forming cells in intact and irradiated mice. CP-88 peptide increases the relative number of CD34+ cells in the blood and bone marrow, leading to expanded hematopoietic stem cells. CP-88 peptide, applied 48 h before bone marrow extraction, stimulates the population of committed colony-forming cells in the normal bone marrow by 33–37% above the normal level. In recipient mice injected with irradiated bone marrow, this peptide was restored practically to normal levels of colony-forming cells in a wide range of doses at intraperitoneal and oral administration. The toxicological results conclude that in humans, considering interspecies extrapolation, the CP-88 peptide can be practically safe with a single and course administration in doses of up to 100 μg/kg. The results of this investigation underscore the significant potential of CP-88 peptide as a hematopoiesis-regulated drug and instill optimism for its future application in medical practice.

  • Open Access

    The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples

    by Vladislav Deigin, Natalia Linkova, Julia Vinogradova, Dmitrii Vinogradov, Victoria Polyakova, Dmitrii Medvedev, Alexander Krasichkov, Olga Volpina

    Peptides show high promise in the targeting and intracellular delivery of next-generation biotherapeutics. The main limitation is peptides’ susceptibility to proteolysis in biological systems. Numerous strategies have been developed to overcome this challenge by chemically enhancing the resistance to proteolysis. In nature, amino acids, except glycine, are found in L- and D-enantiomers. The change from one form to the other will change the primary structure of polypeptides and proteins and may affect their function and biological activity. Given the inherent chiral nature of biological systems and their high enantiomeric selectivity, there is rising interest in manipulating the chirality of polypeptides to enhance their biomolecular interactions. In this review, we discuss the first examples of up-and-down homeostasis regulation by two enantiomeric drugs: immunostimulant Thymogen (L-Glu-L-Trp) and immunosuppressor Thymodepressin (D-Glu(D-Trp)). This study shows the perspective of exploring chirality to remove the chiral wall between L- and D-biomolecules. The selected clinical result will be discussed.


  • Open Access

    Role of Genetic Thrombophilia Markers in Thrombosis Events in Elderly Patients with COVID-19

    by Irina Fevraleva, Daria Mamchich, Dmitriy Vinogradov, Yulia Chabaeva, Sergey Kulikov, Tatiana Makarik, Vahe Margaryan, Georgiy Manasyan, Veronika Novikova, Svetlana Rachina, et al.

    Thrombosis is an extremely dangerous complication in elderly patients with COVID-19. Since the first months of the pandemic, anticoagulants have been mandatory in treatment protocols for patients with COVID-19, unless there are serious contraindications. We set out to discover if genetic thrombophilia factors continue to play a triggering role in the occurrence of thrombosis in patients with COVID-19 with prophylactic or therapeutic anticoagulants. We considered the following genetic markers as risk factors for thrombophilia: G1691A in the FV gene, C677T and A1298C in the MTHFR gene, G20210A and C494T in the FII gene, and (−675) 4G/5G in the PAI-I gene. In a cohort of 176 patients, we did not obtain a reliable result indicating a higher risk of thrombotic complications when taking therapeutic doses of anticoagulants in carriers of genetic markers for thrombophilia except the C494T mutation in the FII gene. However, there was still a pronounced tendency to a higher incidence of thrombosis in patients with markers of hereditary thrombophilia, such as FV G1691A and FII G20210A mutations. The presence of the C494T (Thr165Met) allele in the FII gene in this group of patients showed a statistically significant effect of the mutation on the risk of thrombotic complications despite anticoagulant therapy.


  • Open Access

    Thymodepressin—Unforeseen Immunosuppressor

    by Vladislav I. Deigin, Yulia E. Vinogradova, Dmitry L. Vinogradov, Marina S. Krasilshchikova, Vadim T. Ivanov

    The paper summarizes the available information concerning the biological properties and biomedical applications of Thymodepressin. This synthetic peptide drug displays pronounced immunoinhibitory activity across a wide range of conditions in vitro and in vivo. The history of its unforeseen discovery is briefly reviewed, and the current as well as potential expansion areas of medicinal practice are outlined. Additional experimental evidence is obtained, demonstrating several potential advantages of Thymodepressin over another actively used immunosuppressor drug, cyclosporin A.


  • Open Access

    IGG4-RELATED DISEASE: CONDITION OF THE PROBLEM

    by V. V. Vasilenko, D. L. Vinogradov, Array С. Бурлакова

    Физиологическая роль IgG4 еще не до конца изучена. Известно, что они, как и другие антитела, участвуют в инактивации и удалении из организма веществ, идентифицированных иммунной системой, как чужеродные антигены. Также IgG4 реализуют эффекторные механизмы: связывание со специализированными иммунными клетками, осуществляющими после такого взаимодействия фагоцитоз чужеродных агентов или уничтожение зараженных клеток организма за счет зависимой от антител цитотоксичности. Мнения относительно способности IgG4 активировать комплемент зачастую противоречивы. Повышение концентрации иммуноглобулинов данного подкласса может свидетельствовать не только о развитии инфекционных и аллергических состояний, но и о наличии у пациента IgG4-сопряженной патологии. IgG4-сопряженная патология (IgG4-СП) — относительно недавно выделенная группа патологических состояний, и ее изучение становится все более актуальным. Это связано с тем, что она включает в себя состояния, которые ранее считались самостоятельными нозологическими единицами. В последние годы IgG4-СП диагностируется все чаще, так как получает все большее признание у медицинской общественности. Данный обзор включает новейшую информацию из последних зарубежных публикаций.


  • Open Access

    THE MAIN MARKERS OF AUTOIMMUNE RHEUMATIC DISEASES AND THEIR INTERPRETATION

    by Array С. Бурлакова, V. V. Vasilenko, D. L. Vinogradov

    Целью этой работы является систематизация данных о маркерах аутоиммунных ревматических болезней. В статью включена базовая информация с учетом последних рекомендаций от 2014 года. Весь материал представлен в виде таблиц, для удобного использования в повседневной практике любого специалиста.


  • Open Access

    CAMERON LESIONS: LITERATURE REVIEW AND CASE PRESENTATION

    by V. V. Vasilenko, D. L. Vinogradov, M. S. Khamidulina

    СИНДРОМ КЭМЕРОНА: ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ


    • 1 January 2009
      • Vol. 87  (10) , 59-60

    [Neurologic manifestations of HIV infection].

    by A I Mazus, I I Leven, D L Vinogradov, O V Chigrinets, I V Dukhanina

    The sole universally recognized diagnostic criterion for the affection of central nervous system by immunodeficiency virus is AIDS-dementia complex. Its main pathognomonic feature is progressive intellect failure although most patients do not experience intellect deficit. Instead, they present with other disorders in the central nervous system. This article focuses on their early diagnosis.